News Daily News Ischemic Stroke After LAA Closure May Be Less Severe Than on DOACs Michael O'Riordan November 27, 2023
News Daily News Andexanet Alfa, Reversal Agent for Factor Xa Inhibitors, Boosts Hemostasis Todd Neale June 05, 2023
News Conference News HRS 2020 PINNACLE FLX: New-Generation Watchman Has High Closure Rates, Good Safety Todd Neale May 15, 2020
News Conference News ISC 2019 Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects Todd Neale February 13, 2019
News Features The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine Shelley Wood October 22, 2018
News Daily News Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval Todd Neale May 04, 2018
News Conference News ACC 2018 Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4 Todd Neale March 13, 2018
News Conference News TCT 2017 Longer-term Outcomes of Watchman Reassure as Debate Continues Over How It Should Be Used Todd Neale November 02, 2017
News Features Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond Shelley Wood December 30, 2016
News Daily News Were Problems With the Point-of-Care Device Used in ROCKET AF Kept From the FDA? BMJ Says Yes Todd Neale September 28, 2016
News Conference News ESC 2016 Reversal Agent for Factor Xa Inhibitors Rapidly Reduces Anticoagulant Effects: ANNEXA-4 Todd Neale August 31, 2016
News Daily News FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors Michael O'Riordan August 18, 2016